Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
150 participants
INTERVENTIONAL
2023-03-27
2026-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2
NCT06006143
Screening Evaluation for Studies of the National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NCT00001673
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
NCT00981617
Alcoholism Assessment and Treatment
NCT00106093
Medication Development in Alcoholism: Apremilast Versus Placebo
NCT03175549
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Computer delivered RPI
2 session computer delivered counseling to prevent relapse to hazardous drinking
Relapse Prevention Intervention
2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
Person delivered RPI
2 session counselor delivered counseling to prevent relapse to hazardous drinking
Relapse Prevention Intervention
2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
Treatment as Usual
Counseling for alcohol use available in clinic as treatment as usual
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Relapse Prevention Intervention
2 session intervention to address relapse prevention among people with HIV who have an alcohol use disorder
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Aged 18 years or older
* Must be enrolled in clinical care at Johns Hopkins HIV Clinic.
In addition, meet the following alcohol use criteria:
1. lifetime alcohol use disorder
2. patient reported outcomes (PRO) assessment collected by the Center for AIDS Research (CFAR) Network of Clinical Systems as part of usual clinical care that show in the last 3 years: periods of no or lower risk drinking (e.g. women/men who are drinking \<11/22 drinks per week) and periods of lapse to higher levels of drinking (=\>11/22 drinks per week for women/men)
3. current PRO showing alcohol abstinence or alcohol use at \<11/22 drinks per week for women/men.
Exclusion Criteria
* Non-English speaking because interventions are currently available in English only
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Heidi Hutton, PhD
Role: PRINCIPAL_INVESTIGATOR
Johns Hopkins School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins School of Medicine
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Heidi Hutton
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00288483
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.